Evaluation of a follow-up customized strategy for women treated with methotrexate for an ectopic pregnancy: An observational study.
Ectopic pregnancy
Follow-Up strategy
Methotrexate
Journal
European journal of obstetrics, gynecology, and reproductive biology
ISSN: 1872-7654
Titre abrégé: Eur J Obstet Gynecol Reprod Biol
Pays: Ireland
ID NLM: 0375672
Informations de publication
Date de publication:
May 2019
May 2019
Historique:
received:
18
02
2019
accepted:
26
02
2019
pubmed:
17
3
2019
medline:
18
12
2019
entrez:
17
3
2019
Statut:
ppublish
Résumé
To evaluate a follow-up customized strategy used in women treated with methotrexate for tubal ectopic pregnancy. This observational monocentric study took place from November 2009 to December 2015 in the emergency unit at La Conception University Hospital in Marseille, France. 440 women were treated by methotrexate for tubal ectopic pregnancy. Women were assigned in a classic follow up protocol with a weekly hCG evaluation (conventional protocol) if the drop in hCG between D1 and D4 was inferior to 20% or in an alternative follow up (streamlined protocol) with a hCG evaluation at one month. The main outcome measures were the success rate, the proportion of women requiring several methotrexate injections, and the mean number of consultations per women and duration of the follow-up. During this period, the success rate was 348/440 (79.1%). The rate of women requiring 1, 2, or 3 injections and of women lost to follow-up were comparable between the two protocols. The mean number of consultations per woman was 3.6 ± 1.33 vs. 5.95 ± 2.25 days (p < 0.0001), and the follow-up was 27.5 ± 12 vs. 28.1 ± 15.4 (p = 0.6) respectively in the conventional protocol group and the streamlined. Our customized strategy allows for a decrease in the number of consultations per woman without changing the success rate or the need for methotrexate injection. hCG count drop between D1 and D4 allows for the selection of a low-risk group that can benefit from appropriate aftercare.
Identifiants
pubmed: 30877908
pii: S0301-2115(19)30113-7
doi: 10.1016/j.ejogrb.2019.02.037
pii:
doi:
Substances chimiques
Abortifacient Agents, Nonsteroidal
0
Methotrexate
YL5FZ2Y5U1
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
32-35Informations de copyright
Copyright © 2019 Elsevier B.V. All rights reserved.